-
Substance use outcomes in cocaine-dependent tobacco smokers: A mediation analysis exploring the role of sleep disturbance, craving, anxiety, and depression.
Winhusen TJ, Theobald J, Lewis DF. Substance use outcomes in cocaine-dependent tobacco smokers: A mediation analysis exploring the role of sleep disturbance, craving, anxiety, and depression. Journal of Substance Abuse Treatment 2019;96:53-57
-
Prevalence and patterns of opioid misuse and opioid use disorder among primary care patients who use tobacco.
John WS, Zhu H, Mannelli P, Subramaniam GA, Schwartz RP, McNeely J, Wu L. Prevalence and patterns of opioid misuse and opioid use disorder among primary care patients who use tobacco. Drug and Alcohol Dependence 2019;194:468-475.
-
Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse.
Murphy SM, McCollister K, Leff JA, Yang X, Jeng PH, Lee JD, Nunes EV, Novo P, Rotrosen J, Schackman BR. Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse. Annals of Internal Medicine 2019;170(2):90-98.
-
Health risk perceptions and reasons for use of tobacco products among clients in addictions treatment.
Campbell BK, Le T, Gubner NR, Guydish JR. Health risk perceptions and reasons for use of tobacco products among clients in addictions treatment. Addictive Behaviors 2019;91:149-155.
-
Social functioning outcomes among individuals with substance use disorders receiving internet-delivered community reinforcement approach.
Marino LA, Campbell ANC, Pavlicova M, Hu M, Nunes EV. Social functioning outcomes among individuals with substance use disorders receiving internet-delivered community reinforcement approach. Substance Use & Misuse 2019;54(7):1067-1074.
-
Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: Electronic health record findings.
Winhusen TJ, Theobald J, Kaelber DC, Lewis DF. Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: Electronic health record findings. Addiction 2019;114(8):1462-1470.
-
Prevalence of obesity for opioid- and stimulant-dependent participants in substance use treatment clinical trials.
Hu L, Matthews A, Shmueli-Blumberg D, Killeen TK, Tai B, VanVeldhuisen PC. Prevalence of obesity for opioid- and stimulant-dependent participants in substance use treatment clinical trials. Drug and Alcohol Dependence 2018;190:255-262.
-
Missed opportunities for HIV testing among STD clinic patients.
Traynor SM, Rosen-Metsch L, Feaster DJ. Missed opportunities for HIV testing among STD clinic patients. Journal of Community Health 2018;43:1128-1136.
-
A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction.
Levran O, Correa da Rosa J, Randesi M, Rotrosen J, Kreek MJ. A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLOS One 2018;13(6):e0199951
-
How patient navigators view the use of financial incentives to influence study involvement, substance use, and HIV treatment.
Mitchell SG, Monico LB, Stitzer ML, Matheson T, Sorensen JL, Feaster DJ, Schwartz RP, Metsch LR. How patient navigators view the use of financial incentives to influence study involvement, substance use, and HIV treatment. Journal of Substance Abuse Treatment 2018;94:18-23